PDCD1 and susceptibility to pneumonia measurement: According to the European Society for Medical Oncology (ESMO) guidelines (17), Skin toxicity, gastrointestinal toxicity, liver toxicity, pneumonia, and endocrine disruption are common side effects of PD-1 inhibitors.